BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 103 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2014. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $168,000 | -20.0% | 32,000 | -11.1% | 0.01% | -12.5% |
| Q2 2017 | $210,000 | -34.6% | 36,000 | -7.0% | 0.02% | -33.3% |
| Q1 2017 | $321,000 | +40.8% | 38,700 | -0.4% | 0.02% | +33.3% |
| Q4 2016 | $228,000 | +24.6% | 38,850 | -4.9% | 0.02% | +20.0% |
| Q3 2016 | $183,000 | +18.1% | 40,850 | -0.4% | 0.02% | +25.0% |
| Q2 2016 | $155,000 | +6.9% | 41,000 | -19.8% | 0.01% | -7.7% |
| Q1 2016 | $145,000 | -54.0% | 51,100 | -0.4% | 0.01% | -50.0% |
| Q4 2015 | $315,000 | -41.4% | 51,300 | -5.5% | 0.03% | -46.9% |
| Q3 2015 | $538,000 | -26.5% | 54,300 | -15.2% | 0.05% | -25.8% |
| Q2 2015 | $732,000 | +23.2% | 64,000 | -0.2% | 0.07% | +24.5% |
| Q1 2015 | $594,000 | -99.9% | 64,150 | -8.4% | 0.05% | -11.7% |
| Q4 2014 | $845,504,000 | +96972.8% | 70,050 | +2.9% | 0.06% | -9.1% |
| Q3 2014 | $871,000 | – | 68,050 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 7,637,700 | $77,675,000 | 7.44% |
| Burrage Capital Management LLC | 864,916 | $8,796,000 | 7.13% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,367,670 | $24,079,000 | 3.61% |
| HealthCor Management, L.P. | 4,886,440 | $49,695,000 | 1.76% |
| Ghost Tree Capital, LLC | 500,000 | $5,085,000 | 1.20% |
| Integral Health Asset Management, LLC | 400,000 | $4,068,000 | 1.16% |
| Lisanti Capital Growth, LLC | 472,520 | $4,806,000 | 0.62% |
| Parkman Healthcare Partners LLC | 244,680 | $2,488,000 | 0.58% |
| Baker Brothers Advisors | 12,710,818 | $129,269,000 | 0.56% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,605,380 | $26,497,000 | 0.56% |